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Abstract
Objective: Interleukin-17 (IL-17), a potent proinflammatory cytokine, has been implicated in allograft rejection. We analyzed the efficacy of
an adenoviral vector expressing an IL-17 inhibitor in delaying acute allograft rejection in a rat model of heart transplantation, and the biological
mechanisms underlying the protective effect.Methods:We constructed an adenoviral vector expressing a soluble IL-17 receptor-immunoglobulin
(IL-17R-Ig) fusion protein. IL-17R-Ig activity was assessed by inhibition of IL-17-induced IL-6 release in HeLa cells preincubated with the vector.
Intracoronary vector administration was performed in F344 donor hearts that were placed as vascularized grafts into Lewis hosts. Inflammatory
cells infiltrating the graft were analyzed by immunohistology. Cytokine transcripts in the graft were determined by real-time RT-PCR. Results: IL-
17R-Ig gene transfer resulted in prolonged allograft survival (16.1  3.1 days vs 10.3  2.5 days with control virus and 10.1  2.1 days with virus
dilution buffer alone; p < 0.001). IL-17R-Ig gene transfer reduced inflammatory cell infiltrates, especially monocytes/macrophages and CD4+ T
cells ( p < 0.05). It also reduced intragraft cytokine transcripts for interferon-g and transforming growth factor-b ( p < 0.05) and, to a lesser
extent, IL-1b and tumor necrosis factor-a ( p = 0.083). Conclusions: Local expression of soluble IL-17 receptor-immunoglobulin attenuates T
helper type 1 (Th1) cytokine responses and leukocyte infiltration in rat cardiac allografts, thereby mediating prolonged graft survival. Intragraft
IL-17 inhibition may be useful as an adjuvant therapy to systemic immunosuppression in heart transplantation.
# 2006 Elsevier B.V. All rights reserved.
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Proinflammatory cytokines mediate inflammatory and
immune responses during ischemia—reperfusion injury and
early rejection after heart transplantation in humans [1,2].
Interleukin-17 (IL-17) is a potent proinflammatory cytokine
originally referred to as cytotoxic T lymphocyte-associated
serine esterase-8 (CTLA-8) [3]. Murine IL-17 is a 21-kDa§ Abstracts presented at the 24th Annual Meeting and Scientific Sessions of
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doi:10.1016/j.ejcts.2006.01.052glycoprotein, consisting of 147 amino acids, with a 63% amino
acidhomologywithhuman IL-17, butnoobvioushomologywith
other cytokines (except a 57% homology with vIL-17 from
Herpesvirus saimiri) [3—6]. Activated CD8+ and CD8+CD45RO+
memory T cells produce IL-17 in humans [7]. Although CD4+
cells can produce IL-17 in mice [8], the cytokine is
preferentially produced by TCRa/b+CD4CD8 T cells at
physiologically relevant levels [9]. A high-affinity receptor for
IL-17 (IL-17R) has been isolated frommouse EL4 thymomacells
[5]. This receptor shares no homology with other cytokine
receptor families and shows a ubiquitous tissue distribution.
IL-17 stimulates stromal cells and macrophages to secrete
a host of inflammatory mediators, such as IL-1b, IL-6, IL-8,
tumor necrosis factor-a (TNF-a), granulocyte-colony stimu-
lating factor (G-CSF), monocyte chemoattractant protein-1
(MCP-1), and prostaglandin E2 [9,10]. IL-17 has been shown to
induce expression of intercellular adhesion molecule-1
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endothelial cells mediates leukocyte adhesion and contri-
butes to ischemia—reperfusion injury. In addition, IL-17
stimulates proliferation of alloreactive T cells [11], anti-
tumor natural killer (NK) cell activity [12], and maturation of
dendritic cell progenitors in vitro [11]. IL-17-deficient mice
exhibit abnormal contact, delayed-type, and airway hyper-
sensitivity responses, along with impaired T-dependent
antibody production [13]. These abnormalities suggest an
important role for IL-17 in allergen-specific T cell-mediated
immune responses.
Increased expression of IL-17 protein on infiltrating
mononuclear cells was detectable on day 2 after experi-
mental renal transplantation, and preceded IL-6 and IL-8
expression [14]. Elevated IL-17 levels have been associated
with renal graft rejection in humans [14,15]. In a mouse
model of heart transplantation, intraperitoneal administra-
tion of an IL-17 inhibitor (soluble IL-17R-Ig fusion protein)
resulted in prolonged graft survival [11]. However, the
impact of IL-17 inhibition on inflammatory cells infiltrates
and cytokine expression in the graft was not characterized. In
the present study, we used a gene transfer-based approach to
produce the IL-17 inhibitor in the graft itself, as opposed to
systemic administration. Gene therapy is an attractive
approach to organ transplantation because it can be carried
out in the isolated donor organ under well-controlled
conditions immediately before transplantation, and because
the therapeutic factor can be produced in the graft for
extended periods of time. Localized production of the
protective protein minimizes systemic effects.
We constructed an adenoviral vector that expresses a
soluble IL-17R-Ig fusion protein, and we evaluated its efficacy,
alongwith themechanismsunderlying theprotectiveeffect, in
a rat model of acute cardiac allograft rejection.2. Methods
2.1. Construction of the AdIL-17R-Ig vector
The cDNA sequence coding for the IL-17R extracellular
domain was cloned using a RT-PCR protocol from C57BL/6
mouse spleen mRNA. After confirmation by bidirectional
sequencing, the cDNA was subcloned in frame with an XbaI
fragment encoding the constant and hinge region (Fcg
fragment) of mIgG1. The resulting cDNA containing the IL-17R
coding sequence was placed into a CMV promoter-driven
expression cassette in the pC5 plasmid. This allows for the
construction of adenoviral vectors by using a novel method
based on direct DNA ligation [16]. Recombinant adenovirus
AdIL-1R-Ig was generated by pC5 co-transfection with PacI-
restricted viral DNA from AdGFP (a D1-deleted recombinant
adenovirus containing a unique PacI site [16]) onto 293 cells.
Concentrated virus stocks were prepared using two CsCl2
ultracentrifugation gradients and stored in storage buffer
(10 mmol/L Tris—HCl, pH 7.4, 1 mmol/L MgCl2, 10% glycerol)
according to standard protocols. An adenoviral vector
containing no transgene (AdNull) was used as a control.
The titer of AdIL-17R-Ig and AdNull stock preparations
determined by plaque titration assay was 1  1011 plaque
forming units (PFU)/mL (virus particles/PFU ratio 5—10).IL-17R-Ig protein expression was assessed by Western blot
analysis of HeLa cells preincubated with AdIL-17R-Ig, using
two different mAbs, each one recognizing one component of
the fusion protein: goat anti-mouse IL-17R mAb (RnD;
catalogue number AF 448) and goat anti-mouse IgG (Fcg
fragment-specific) mAb. IL-17R-Ig activity was determined by
preincubating 3T3 cells with either AdIL-17R-Ig or control
vector at a multiplicity of infection (MOI) of 200 for 24 h,
followed by stimulation with recombinant IL-17 or IL-1b for
6 h; the resulting IL-6 release was assessed by ELISA.
2.2. Gene transfer and heart transplantation
All animals received humane care in compliance with the
European Convention on Animal Care and the study was
approved by the local institutional ethics committee. Male
Fischer rats (F344; 8—12 weeks old) were used as heart
donors and male Lewis rats (LEW; same age) as recipients
(both strains were from IFFA CREDO, L’Arbresle, France). Ex
vivo gene transfer into the donor heart was performed by
intracoronary instillation of vector containing solution
immediately before transplantation. First, donor hearts
were instilled slowly with 500 mL phosphate-buffered saline
PBS (without Ca++/Mg++; pH 7.4), followed by 200 mL virus
containing solution, while allowing efflux through the right
pulmonary artery. This artery was then clamped and 400 mL
solution containing 1010 PFU viral vector were instilled slowly
into the coronary arteries. Heterotopic cardiac grafts were
placed in the abdominal position of rats anesthetized by
isoflurane inhalation. Graft survival was monitored by daily
abdominal palpation. Rejection, defined as total cessation of
heart beating, was confirmed by direct graft examination.
2.3. Immunohistology
Immunohistology was performed on cryostat sections of
heart samples harvested 6 days after transplantation. Rats
were sacrificed by lethal pentobarbital injection, perfused
with ice-cold PBS, and hearts were immediately frozen in
OCT-compound. Four series of 8-mm sections per heart (n = 4
per group) were cut at 500-mm steps parallel to the atrio-
ventricular groove from the cardiac apex to the basis. IL-17R-
Ig protein expression was visualized by immunostaining using
goat anti-mouse IgG (Fcg fragment-specific) mAb, followed
by biotin-conjugated anti-goat IgG (Jackson ImmunoRe-
search Lab.), StreptABComplex/HRP, and Nickel-DAB/H2O2
(Dako). Leukocytes infiltrating the graft were immunostained
with the following primary mouse mAbs: anti-ED1-like (1C7)
detecting monocytes/macrophages, anti-TCRab (R73)
detecting T lymphocytes bearing TCRab, anti-CD8a (OX-8;
all from PharMingen) detecting cytotoxic T lymphocytes and
NK cells), anti-CD4 (W3/25; Accurate Chemicals) detecting
CD4+ T lymphocytes and macrophages, and irrelevant mouse
(MOPC-31C; PharMingen) as a control. Detection steps were
biotin-conjugated rabbit F(ab0)2 anti-mouse Ig (Jackson
ImmunoResearch), followed by StreptABComplex/HRP and
DAB/H2O2 (Dako). Images were acquired with a Hyper-HAD-
Axioscop microscope and an Axiocam-MRcD camera (Zeiss).
Morphometric analysis was performed in eight representative
microscopic fields (100) per cardiac section using the NIH-
Image-1.62 program. Positive-staining areas for each marker
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respective sections.
2.4. Quantitative RT-PCR
PBS-perfused hearts (n = 4 per group) were excised, and
about 300 mg of apical myocardium was placed in ice-cold
PBS and cut into thin slices, then submerged into RNAlater
Stabilization Reagent. Total RNA was extracted with the
Qiagen RNeasy midi kit. DNase-treated RNA was used to
generate cDNA, using the reverse transcriptase Omniscript
(Qiagen), random hexamer (Promega), and RNase inhibitor
(Roche). cDNA equivalent to 100 ng of total RNAwas used for
each PCR reaction. Transcript levels for cytokines were
measured by quantitative real-time PCR (Rotor-Gene 2000,
Corbett Research), using the SYBR-green dye. Constitutively
expressed hypoxanthine phosphoribosyltransferase (HPRT)
was selected as endogenous control to correct for potential
variation in RNA loading or efficiency of the amplification
reaction. Primer sequences were as follows: IFN-g,
50-tcatggccctctctggctgttac-30 (sense) and 50-caagagga-
ggctctttccttccatag-30 (antisense); IL-1b, 50-cttcaaatctcacag-
cagcatctcg-30 (sense) and 50-tccacgggcaagacataggtagc-30
(antisense); TNF-a, 50-ctgtgcctcagcctcttctcattc-30 (sense)
and 50-ttgggaacttctcctccttgttgg-30 (antisense); TGF-b, 50-
ctaatggtggaccgcaacaacg-30 (sense) and 50-tctggcactgcttccc-
gaatg-30 (antisense); RANTES, 50-ccatatggctgcgacaccactc-30
(sense) and 50-gcacacacttggcggttcctt-30 (antisense); HPRT,
50-ctcatggactgattatggacaggactg-30 (sense) and 50-cagcgctt-
taatgtaatccagcaggtc-30 (antisense). The threshold cycle (CT)
was defined as the fractional cycle number at which the
reported fluorescence reached a defined level. Target gene
normalized to HPRTwas expressed as DCT (CT of target gene
minus CT of HPRT) [17].
2.5. Statistical analysis
Graft survival is shown as mean survival time (SD) and by
Kaplan—Meier cumulative survival curves. Statistical sig-
nificance of differences in graft survival between AdIL-17R-
Ig, AdNull, and PBS was analyzed using product-limit
(Kaplan—Meier) survival estimates by Log Rank statistics
(JMP program, version 5; SAS Institute). Immunohistological
data are shown as median values (range). Statistical
significance of differences in intragraft leukocyte infiltrates
and cytokine transcripts between IL-17R-Ig and mock gene
transfer was analyzed by Mann—Whitney U-test. A p-value
<0.05 was considered to be statistically significant.Fig. 1. (A—C) detection of transgene expression in cardiac allografts. (A) AdIL-
17R-Ig. Immunostaining for mouse IgG, Fcg fragment-specific, at day 6 post-
transplant (arrows: positive-staining cells (Nickel—DAB/H2O2). (B) AdNull
(control); immunostaining for mouse IgG. (C) AdIL-17R-Ig; staining with iso-
type-matched control antibody. (D) Kaplan—Meier survival curves of allografts
receiving AdIL-17R-Ig ( p < 0.001 vs either control), AdNull, or PBS.3. Results
3.1. IL-17R-Ig gene transfer prolongs cardiac graft
survival
To establish the method of adenovirus-mediated ex vivo
gene transfer into the donor heart, we performed pre-
liminary studies using an adenoviral vector containing the
LacZ reporter gene (AdLacZ) in rat cardiac isografts (LEW/
LEW). Gene transfer efficiency, assessed by immunohistolo-
gical staining with rabbit anti-b-galactosidase Ab, was higherusing a virus dose of 1010 PFU/heart compared with 109 PFU.
b-gal-positive cells decreased in number by 2.5-fold
between days 5 and 40 post-transplantation. The AdIL-17R-
Ig vector was tested in the allogeneic F344/LEW rat strain
combination after successful functional characterization in
vitro. This comprised demonstration of IL-17R-Ig protein
expression in transduced HeLa cells, and of IL-17 inhibitory
activity in transduced 3T3 cells; the effect of IL-1b
stimulation was unaffected (data not shown). IL-17R-Ig
protein expression in cardiac allografts was visualized by
immunostaining (Fig. 1A—C). Allograft survival in hearts
receiving AdNull (10.3  2.5 days; n = 8) was similar to those
receiving PBS alone (10.1  2.1 days; n = 9), whereas survival
of grafts receiving AdIL-17R-Ig (n = 8) was significantly
prolonged (16.1  3.1 days; p < 0.001 vs AdNull and PBS;
Fig. 1D). A separate group of grafts (n = 4) infused with the
AdLacZ vector showed a similar survival (10.0  2.0 days)
compared with AdNull. Control isografts (LEW/LEW) survived
for >150 days.
3.2. IL-17R-Ig gene transfer reduces graft infiltration by
inflammatory cells
In the AdIL-17R-Ig versus AdNull groups (n = 4 each),
median values (range) for myocardial surface areas staining
positive for ED1-like were 5.0% (3.7—8.3%) versus 17.6%
(12.2—20.7%; p < 0.05); for CD4, 5.1% (4.2—10.0%) versus
17.2% (11.9—26.6%; p < 0.05); for CD8a, 8.9% (7.1—12.2%)
versus 12.5% (10.8—14.0%; p = 0.083), and for TCRab, 13.1%
(11.7—13.4%) versus 13.0% (7.0—15.0%; NS). Thus, IL-17R-Ig
gene transfer reduced graft infiltration by monocytes/
macrophages and CD4+ cells by approximately 3.5-fold
(Fig. 2).
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Fig. 2. Immunohistological analysis of inflammatory cells infiltrating the graft. Upper panels: photomicrographs of heart sections in the AdIL-17R-Ig and AdNull groups
(n = 4 each) immunostained with the indicated mAbs. Lower panel: quantitative analysis of percent myocardial surface area staining positive for each mAb (AdIL-17R-
Ig, opened squares; AdNull, closed circles). Horizontal bars are median values.3.3. IL-17R-Ig gene transfer reduces cytokine transcripts
in the graft
Compared with mock gene transfer, IL-17R-Ig gene
transfer reduced cytokine transcripts for IFN-g ( p < 0.05),
TGF-b ( p < 0.05), IL-1b ( p = 0.083), and TNF ( p = 0.083),
but not RANTES (Fig. 3). Of note, a change in DCT values by 1
unit corresponds to a change in cytokine transcripts by
several folds; hence, differences in cytokine transcripts
between the two groups were substantial.Fig. 3. Real-time RT-PCR analysis of cytokine transcripts in allografts after
AdIL-17R-Ig (opened squares) or mock gene transfer (closed circles; n = 4
each). Data are shown as DCT (more negative values indicate higher cytokine
transcript levels) [17]. Horizontal bars are median values.4. Discussion
Blocking of a cytokine’s activity (e.g., using mAbs or
soluble receptors) is a rational approach to the immunosup-
pressive therapy of allograft rejection. Here we show that
localized expression of a soluble IL-17R-Ig fusion protein in
donor hearts mitigates tissue inflammation and delays acute
allograft rejection in a rat model. The protective effect was
associated with decreased numbers of macrophages, CD4+ T
cells, and marginally, CD8+ T cells infiltrating the graft.
Moreover, IL-17R-Ig gene transfer reduced cytokine tran-
scripts for IFN-g, TGF-b, IL-1b, and TNF-a. These results
suggest that IL-17R-Ig may act by down-regulating early-
phase cytokines induced by ischemia—reperfusion injury,
such as TNF-a and IL-1b [18], together with T helper (Th)
type 1 cytokines, such as IFN-g. Th1 cytokine responses have
been associated with acute allograft rejection. Our results
are consistent with in vitro data showing that IL-17 up-
regulates IFN-g and IL-1b in macrophages [10]. In turn, IFN-g
stimulates macrophages to produce IL-1b, TNF-a, IL-12, and
other proinflammatory cytokines. Thus, down-regulation of
IFN-g may be an important mechanism by which IL-17
inhibition protects the graft. Additional mechanisms sup-
ported by previous in vitro data include inhibition of IL-17-
induced proliferation of alloreactive T cells, and of IL-17-
induced maturation of dendritic cell progenitors [11].
Our results are in good agreement and extend previous
data by Antonysamy et al. [11] showing prolonged mouse
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intraperitoneal injections of purified IL-17R-Ig protein (on
post-transplantation days 0—6). However, leukocyte infil-
trates and cytokine expression in the graft were not
characterized in this study. Using gene transfer technology,
we have investigated the effect of localized IL-17R-Ig
production in the graft itself, as opposed to the systemic
approach utilized in the previous study [11]. Intragraft gene
transfer may be more or less effective than the systemic
approach, depending on several factors including the
therapeutic molecule itself. For instance, intragraft gene
transfer of CTLA-4-Ig, an immunomodulatory protein, was
more effective and caused less systemic immunosuppression
than systemic CTLA-4-Ig protein treatment in a rat heart
transplantation model [19]. However, this study lacked a
direct comparison between intragraft and systemic CTLA-4-Ig
gene transfer, because the systemic approach consisted of
recombinant CTLA-4-Ig protein administration. This
approach suffers from several limitations including inter-
batch variability of CTLA-4-Ig activity. In another study, gene
transfer of heme oxygenase-1, a cytoprotective enzyme,
achieved long-term cardiac allograft survival in a majority of
mice after intravenous vector injection, but not after direct
vector administration to the graft [20]. Because heme
oxygenase-1 overexpression in the spleen was detected after
intravenous vector injection only, it was postulated that
modification of alloimmune responses in the spleen might be
central to the protective effect of heme oxygenase-1. These
results were consistent with data in HO-1 transgenic mice
showing prolonged allograft survival of normal donor hearts
placed in HO-1 transgenic hosts, whereas HO-1 transgenic
donor hearts were promptly rejected by normal hosts [21].
These observations illustrate the fact that intragraft and
systemic overexpression of a therapeutic gene may induce
different biological effects; hence, the interest of studying
intragraft IL-17R-Ig gene transfer.
Although IL-17R-Ig gene transfer delayedacute rejection, it
ultimately failed to prevent it. This result is not surprising
considering the molecular redundancy in cytokine activation
cascades, whereby multiple cytokines can activate down-
stream effector pathways of tissue inflammation. The present
proof-of-concept studydoes not permit to drawany conclusion
regarding possible clinical applications. Data in rodent
models of transplantation are of limited usefulness in humans.
Nevertheless, our results suggest that further investigationson
IL-17 inhibition as a potential adjuvant therapy in transplanta-
tion are warranted. Future studies will need to explore
possible synergistic effects of IL-17 inhibition and currently
used immunosuppressive agents in clinically more relevant
transplantation models in nonhuman primates.Acknowledgments
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